CompanyPRQRNasdaqLeiden

ProQR Therapeutics N.V.

ProQR Therapeutics develops RNA therapies using its Axiomer platform technology, which leverages ADAR-mediated editing to correct single nucleotide mutations in RNA.

Stories only

SEC EDGAR ClinicalTrials.gov proqr.com

6-KSep 23Latest SEC filing, period to Sep 23

Sep 23Latest story

September 2026

ProQR names Chris Hart as Chief Data and AI Officer, adds Thomas Wolf to board

Sep 23PeopleProQR Therapeutics N.V.

ProQR doses first participant in Phase 1 trial of AX-0811

Sep 9Clinical readoutProQR Therapeutics N.V.

August 2026

ProQR reports Q2 2026 results, cites first Axiomer clinical validation from AX-0810 data

Aug 13PublicationProQR Therapeutics N.V.

July 2026

ProQR Therapeutics files prospectus for resale of up to 3,030,303 shares

Jul 15FinancingProQR Therapeutics N.V.